Funds › PSP Research LLC
PSP Research LLC
13F for Q3 2026, filed Oct 21, 2026. 44 positions worth $145.8M.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of PSP Research LLC in the latest 13F quarter?
Using 13F.ai, how has PSP Research LLC's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of PSP Research LLC's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q3 2026
Largest first. Common shares only.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | iShares Tr 0-3 Mth Treasury | 700,000 | $70.5M | 48.3% | Unchanged | 13F ↗ |
| 2 | Spdr Series Trust St Str Sp Biot | 386,500 | $60.9M | 41.8% | -32.2% | 13F ↗ |
| 3 | SERA Sera Prognostics, Inc. | 2.40M | $5.0M | 3.4% | New | 13F ↗ |
| 4 | HALO Halozyme Therapeutics, Inc. | 3,000 | $331.2K | 0.2% | -57.1% | 13F ↗ |
| 5 | MDGL Madrigal Pharmaceuticals, Inc. | 600 | $302.4K | 0.2% | Unchanged | 13F ↗ |
| 6 | EXEL Exelixis, Inc. | 5,000 | $292.1K | 0.2% | -37.5% | 13F ↗ |
| 7 | RPRX Royalty Pharma plc | 5,000 | $291.8K | 0.2% | -54.5% | 13F ↗ |
| 8 | ARGX argenx SE · ADR | 300 | $287.7K | 0.2% | -53.2% | 13F ↗ |
| 9 | NRIX Nurix Therapeutics, Inc. | 12,000 | $284.5K | 0.2% | -52.0% | 13F ↗ |
| 10 | TGTX TG Therapeutics, Inc. | 5,000 | $278.9K | 0.2% | -50.0% | 13F ↗ |
| 11 | TARS Tarsus Pharmaceuticals, Inc. | 3,500 | $275.1K | 0.2% | -50.0% | 13F ↗ |
| 12 | HRMY Harmony Biosciences Holdings, Inc. | 7,000 | $274.8K | 0.2% | -30.0% | 13F ↗ |
| 13 | ARQT Arcutis Biotherapeutics, Inc. | 10,000 | $264.3K | 0.2% | -49.2% | 13F ↗ |
| 14 | KNSA Kiniksa Pharmaceuticals International, plc | 3,500 | $261.1K | 0.2% | -30.0% | 13F ↗ |
| 15 | SUPN Supernus Pharmaceuticals | 6,000 | $258.2K | 0.2% | Unchanged | 13F ↗ |
| 16 | IMNM Immunome, Inc. | 12,000 | $258.1K | 0.2% | -33.3% | 13F ↗ |
| 17 | NBIX Neurocrine Biosciences, Inc. | 1,800 | $255.3K | 0.2% | -40.0% | 13F ↗ |
| 18 | ORKA Oruka Therapeutics, Inc. | 3,000 | $249.9K | 0.2% | Unchanged | 13F ↗ |
| 19 | TNGX Tango Therapeutics, Inc. | 10,000 | $249.5K | 0.2% | Unchanged | 13F ↗ |
| 20 | DFTX Definium Therapeutics, Inc. | 6,500 | $247.4K | 0.2% | -35.0% | 13F ↗ |
| 21 | RVMD Revolution Medicines, Inc. | 1,200 | $246.3K | 0.2% | Unchanged | 13F ↗ |
| 22 | ALKS Alkermes plc | 6,000 | $243.1K | 0.2% | Unchanged | 13F ↗ |
| 23 | AUPH Aurinia Pharmaceuticals Inc | 15,000 | $242.9K | 0.2% | -50.0% | 13F ↗ |
| 24 | INCY Incyte Corporation | 2,000 | $242.7K | 0.2% | -62.3% | 13F ↗ |
| 25 | NTLA Intellia Therapeutics, Inc. | 20,000 | $241.2K | 0.2% | Unchanged | 13F ↗ |
| 26 | IMVT Immunovant, Inc. | 7,000 | $236.5K | 0.2% | -46.2% | 13F ↗ |
| 27 | STOK Stoke Therapeutics, Inc. | 9,000 | $234.0K | 0.2% | -25.0% | 13F ↗ |
| 28 | KRYS Krystal Biotech, Inc. | 692 | $230.1K | 0.2% | Unchanged | 13F ↗ |
| 29 | ASND Ascendis Pharma A/S | 1,000 | $227.8K | 0.2% | -33.3% | 13F ↗ |
| 30 | SNDX Syndax Pharmaceuticals, Inc. | 12,000 | $225.6K | 0.2% | -40.0% | 13F ↗ |
| 31 | KYMR Kymera Therapeutics, Inc. | 2,000 | $223.6K | 0.2% | -50.0% | 13F ↗ |
| 32 | DNTH Dianthus Therapeutics, Inc. | 2,500 | $220.1K | 0.2% | Unchanged | 13F ↗ |
| 33 | TRVI Trevi Therapeutics, Inc. | 15,000 | $214.8K | 0.1% | -50.0% | 13F ↗ |
| 34 | MIRM Mirum Pharmaceuticals, Inc. | 2,500 | $213.7K | 0.1% | Unchanged | 13F ↗ |
| 35 | IMCR Immunocore Holdings plc · ADR | 7,000 | $212.0K | 0.1% | -53.8% | 13F ↗ |
| 36 | PTGX Protagonist Therapeutics, Inc. | 1,500 | $211.3K | 0.1% | -50.0% | 13F ↗ |
| 37 | EWTX Edgewise Therapeutics, Inc. | 5,000 | $203.0K | 0.1% | Unchanged | 13F ↗ |
| 38 | ORIC Oric Pharmaceuticals, Inc. | 13,000 | $175.1K | 0.1% | Unchanged | 13F ↗ |
| 39 | DYN Dyne Therapeutics, Inc. | 10,000 | $161.1K | 0.1% | -50.0% | 13F ↗ |
| 40 | CMPS COMPASS Pathways Plc · ADR | 10,000 | $124.4K | 0.1% | -44.4% | 13F ↗ |
| 41 | OCUL Ocular Therapeutix, Inc. | 15,000 | $115.0K | 0.1% | Unchanged | 13F ↗ |
| 42 | CTMX CytomX Therapeutics, Inc. | 39,400 | $107.2K | 0.1% | Unchanged | 13F ↗ |
| 43 | ARDX Ardelyx, Inc. | 30,000 | $102.6K | 0.1% | -50.0% | 13F ↗ |
| 44 | OLMA Olema Oncology, Inc. | 10,000 | $86.4K | 0.1% | Unchanged | 13F ↗ |
Changes since Q2 2026
1 new, 0 added to, 27 trimmed, 32 exited, 16 unchanged. By estimated dollars.
New positions (1)
| Position | Shares | Change | Est. dollars |
|---|---|---|---|
| SERA Sera Prognostics, Inc. | 2.40M | New | $5.0M |
Added to (0)
None this quarter.
Trimmed (27)
| Spdr Series Trust St Str Sp Biot | 386,500 | -32.2% | -$28.9M |
| HALO Halozyme Therapeutics, Inc. | 3,000 | -57.1% | -$441.6K |
| INCY Incyte Corporation | 2,000 | -62.3% | -$400.5K |
| RPRX Royalty Pharma plc | 5,000 | -54.5% | -$350.2K |
| ARGX argenx SE · ADR | 300 | -53.2% | -$327.0K |
| NRIX Nurix Therapeutics, Inc. | 12,000 | -52.0% | -$308.2K |
| TGTX TG Therapeutics, Inc. | 5,000 | -50.0% | -$278.9K |
| TARS Tarsus Pharmaceuticals, Inc. | 3,500 | -50.0% | -$275.1K |
| ARQT Arcutis Biotherapeutics, Inc. | 10,000 | -49.2% | -$256.4K |
| IMCR Immunocore Holdings plc · ADR | 7,000 | -53.8% | -$246.6K |
Exited (32)
| IRON Disc Medicine, Inc. | 8,000 | Exited | -$585.1K |
| RAPP Rapport Therapeutics, Inc. | 14,000 | Exited | -$583.4K |
| RARE Ultragenyx Pharmaceutical Inc. | 17,000 | Exited | -$567.6K |
| GLUE Monte Rosa Therapeutics, Inc. | 23,000 | Exited | -$556.6K |
| IONS Ionis Pharmaceuticals, Inc. | 6,800 | Exited | -$539.2K |
| PHVS Pharvaris N.V. | 15,000 | Exited | -$518.7K |
| ACAD ACADIA Pharmaceuticals Inc. | 19,766 | Exited | -$500.1K |
| PTCT PTC Therapeutics, Inc. | 6,000 | Exited | -$489.4K |
| CLDX Celldex Therapeutics, Inc. | 13,000 | Exited | -$483.7K |
| COGT Cogent Biosciences, Inc. | 12,000 | Exited | -$464.4K |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q3 2026.
Filings
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer